Complications of Coronary Angiography and Vascular Access Management

Definition and scope

Coronary angiography is an invasive fluoroscopic procedure in which contrast media are injected selectively into the epicardial coronary arteries through a catheter advanced from a peripheral artery to the aortic root and coronary ostia. It remains the reference standard for defining the extent of coronary artery disease because it provides anatomical information while permitting functional assessment and, when appropriate, immediate percutaneous coronary intervention (PCI).

Complications are uncommon, but their clinical spectrum ranges from transient arrhythmias and minor access-site bleeding to myocardial infarction, stroke, coronary perforation, haemodynamic collapse, acute kidney injury, and death. The risk profile differs between diagnostic angiography and PCI, and is strongly influenced by the clinical setting, vascular access route, anticoagulation, renal function, age, comorbidity, and procedural complexity.

Overall incidence and major complications

Complications during diagnostic coronary angiography occur in approximately 2% of patients. Serious events such as stroke and myocardial infarction occur in fewer than 1%, while mortality is generally below 0.1% in contemporary series. Reported risks vary according to the population and definitions used.

In another large diagnostic-catheterization analysis, mortality was approximately 0.2%, myocardial infarction approximately 0.05%, stroke approximately 0.07%, serious ventricular arrhythmia approximately 0.5%, and major vascular complications approximately 1%. These figures illustrate the variation produced by differences in patient selection, procedural definitions, and institutional practice.

Complications are more frequent during PCI than during purely diagnostic angiography. Elective PCI has reported mortality of 0.1–0.3%, large myocardial infarction in fewer than 3%, and stroke in 0.1–0.4%. Risk is substantially higher in older patients, emergency or urgent procedures, chronic kidney disease, ST-segment elevation myocardial infarction, and cardiogenic shock.

Patient-related and procedural risk factors

The risk of adverse events is increased by:

• advanced age;

• diabetes mellitus;

• chronic kidney disease or renal failure;

• congestive heart failure;

• prior stroke;

• emergency coronary angiography or PCI;

• cardiogenic shock;

• ST-segment elevation myocardial infarction;

• extensive vascular calcification;

• female sex;

• low body mass index;

• larger arterial sheaths;

• greater intensity of procedural anticoagulation;

• complex coronary anatomy and technically difficult PCI.

For peri-procedural stroke specifically, advanced age, diabetes, emergency angiography, previous stroke, renal failure, and heart failure have been identified as important risk factors. Severe atherosclerosis of the axillary or subclavian arteries may increase the risk of embolization.

Risk assessment should be individualized. There are no absolute contraindications to coronary angiography in the general sense; the decision depends on balancing the expected diagnostic or therapeutic benefit against the patient’s specific procedural risks.

Vascular access and access-site complications

Radial and femoral access

Radial access is generally preferred for coronary angiography and PCI because it is associated with fewer vascular and bleeding complications than femoral access. In patients with acute coronary syndrome, randomized evidence has demonstrated lower rates of access-site bleeding, surgical repair, and blood transfusion with radial access. Radial access has also been associated with lower overall major adverse cardiac events and mortality in pooled analyses of randomized trials.

Femoral access remains appropriate in selected patients, particularly when haemodynamic circumstances or technical considerations make radial access unsuitable. The choice should account for the clinical condition, arterial anatomy, equipment requirements, and operator expertise.

Brachial access is associated with more vascular complications than either radial or femoral access, whereas radial access has the lowest reported frequency among these routes.

Femoral-access complications

Vascular complications occur after approximately 3–7% of femoral PCI procedures. They may prolong hospitalization and increase morbidity, mortality, and cost. Presentations include:

• local haematoma;

• pseudoaneurysm;

• arteriovenous fistula;

• arterial dissection;

• arterial thrombosis;

• limb-threatening ischaemia;

• retroperitoneal haemorrhage;

• vascular injury requiring surgical or endovascular treatment.

The risk is affected by the puncture site. Entry above the inguinal ligament substantially increases the likelihood of retroperitoneal haemorrhage. Puncture distal to the femoral bifurcation is associated with pseudoaneurysm and arteriovenous fistula.

Reported major femoral complications include pseudoaneurysm in approximately 0.4%, arteriovenous fistula in 0.2%, limb-threatening ischaemia in 0.1%, and retroperitoneal haemorrhage in 0.4%. Retroperitoneal bleeding and limb-threatening ischaemia are particularly serious and are associated with a two- to tenfold increase in 30-day mortality after PCI.

Predisposing factors include older age, female sex, low body mass index, renal insufficiency, larger sheath diameter, heavy vascular calcification, and greater anticoagulation intensity.

Radial-access complications

Radial access markedly reduces major vascular and bleeding complications compared with femoral access. Complications can nevertheless occur at the wrist or along the radial artery and require surveillance after sheath removal. The source material emphasizes the overall reduction in vascular and bleeding events with radial access but does not provide a detailed classification or management algorithm for individual radial-artery complications.

Recognition of access-site bleeding

Early post-procedure hypotension should prompt consideration of inadequate fluid replacement and occult retroperitoneal haemorrhage, particularly after femoral access. A falling haemoglobin concentration, expanding groin swelling, abdominal or flank discomfort, tachycardia, or persistent hypotension should increase concern for clinically significant bleeding, although the source material does not specify a diagnostic imaging pathway.

Vascular closure devices and haemostasis

Femoral access

After femoral procedures, haemostasis may be achieved by:

• direct manual compression; or

• a vascular closure device using a clip, collagen plug, sealant, or suture-based mechanism.

Closure devices shorten the period of supine bed rest, commonly from approximately 6 hours to 2–4 hours, and may improve patient satisfaction. However, they have not been definitively shown to reduce access-site complications compared with manual compression.

Potential complications of closure devices include:

• infection;

• embolization;

• limb ischaemia;

• arterial occlusion.

They should be avoided in heavily diseased vessels, where the likelihood of device-related complications is greater. Comparative evidence is insufficient to establish a clear advantage of one closure-device category over another. Infections may be more frequent with suture-based systems, whereas occlusions have been reported more often with hybrid devices.

Radial access

Following radial procedures, the sheath is removed and a wristband with an air-filled cushion provides local pressure while preserving radial-artery flow. Bed rest is generally limited to approximately 2 hours while the air is gradually released.

Bleeding and anticoagulation

Most bleeding after diagnostic angiography is minor. More serious bleeding usually occurs in association with a vascular complication, particularly femoral-site injury or retroperitoneal haemorrhage.

Procedural anticoagulation during diagnostic angiography should be adjusted according to:

• procedure duration;

• patient body weight;

• renal function;

• other relevant comorbidities.

The objective is to provide adequate procedural anticoagulation while limiting bleeding, particularly at the time of sheath removal. The use of radial rather than femoral access substantially reduces access-related bleeding.

In patients requiring PCI and long-term anticoagulation, the traditional combination of an anticoagulant with dual antiplatelet therapy markedly increases bleeding. The default strategy after recent PCI is generally dual antithrombotic treatment with an anticoagulant and a P2Y12 inhibitor. Aspirin may be added for up to 30 days when coronary-thrombotic risk is particularly high and bleeding risk is considered low. In this setting, clopidogrel is the preferred P2Y12 inhibitor and a direct oral anticoagulant is the preferred anticoagulant.

Coronary dissection and perforation

Iatrogenic coronary dissection

Catheter manipulation, guidewire passage, balloon inflation, and other PCI manoeuvres may disrupt the coronary wall. A dissection extending into the media or adventitia can compromise the true lumen and produce myocardial ischaemia. Most important intra-procedural dissections can be treated promptly with coronary stenting, although significant residual dissections of the treated artery have been reported in approximately 1.7% of patients.

Residual dissection is clinically important because it increases the risk of:

• post-procedural myocardial infarction;

• emergency coronary artery bypass grafting;

• stent thrombosis;

• mortality.

Guide-catheter trauma is an additional mechanism, distinct from balloon- or device-related barotrauma.

Coronary perforation

Coronary perforation is uncommon during PCI, occurring in approximately 0.2–0.5% of procedures. It is more frequent with atheroablative devices and hydrophilic wires than with conventional balloon angioplasty or standard guidewires.

The clinical consequences depend on the rate and location of blood loss. Rapid perforation may cause cardiac tamponade and haemodynamic collapse within minutes. Prompt recognition is therefore essential. The source material identifies urgent treatment as necessary but does not provide a detailed procedural treatment algorithm.

Arrhythmias

Ventricular and atrial arrhythmias may occur during angiography. Contrast injection itself can provoke rhythm disturbances. Particular care is required during right coronary artery injection: deep cannulation and direct injection into the conus branch may precipitate ventricular fibrillation.

During ventriculography, mechanical contact between the catheter and ventricular wall may produce:

• isolated premature ventricular complexes;

• runs of ventricular tachycardia;

• other ventricular arrhythmias.

These rhythm disturbances commonly resolve after catheter repositioning and often require no specific medical treatment. Persistent or severe arrhythmias, especially ventricular fibrillation, represent an emergency and require immediate procedural management, although specific resuscitation protocols are not detailed in the source material.

Embolic and cerebrovascular complications

Embolization is rare but may affect:

• the coronary circulation;

• the central nervous system;

• peripheral arteries.

Potential embolic material includes thrombus forming on or within the catheter, dislodged atherosclerotic plaque, and material mobilized by guidewire manipulation or contrast injection. Marked calcification of the axillary or subclavian arteries increases the likelihood of embolization.

Peri-procedural stroke risk is higher in patients with advanced age, diabetes, prior stroke, renal failure, heart failure, and emergency procedures. Careful catheter manipulation and appropriate access selection are therefore important components of prevention.

Contrast-agent reactions

Allergic or other contrast-agent reactions are among the more common complications of coronary angiography, with a reported frequency of approximately 0.37% in one risk table. The source material does not describe the clinical classification, prophylaxis, or treatment of contrast reactions in detail.

Low-osmolar and iso-osmolar contrast agents are identified as the safest agents for coronary angiography.

Contrast-induced acute kidney injury

Definition

Contrast-induced acute kidney injury is defined as an increase in serum creatinine of at least 0.5 mg/dL or at least 25% above baseline, developing generally within 24–72 hours after intravascular contrast exposure in the absence of another identifiable cause.

Pathophysiology

The mechanism is incompletely understood. Toxic injury related to the passage of iodine molecules through the renal interstitium is implicated. Contrast agents also promote osmotic diuresis, which has implications for post-procedure fluid management.

Incidence and clinical importance

The incidence is approximately 2% in low-risk patients but may reach 12–50% in patients with diabetes and established chronic kidney disease. Among patients with moderate-to-severe renal dysfunction, defined in the source material as an estimated glomerular filtration rate below 60 mL/min/1.73 m2, development of contrast-induced acute kidney injury is associated with worse short- and long-term outcomes.

It may prolong hospitalization, increase healthcare costs, and adversely affect both morbidity and mortality.

Prevention and follow-up

Risk assessment before angiography and appropriate pre- and post-procedure practices can substantially mitigate the risk. The post-procedure material recommends liberalizing fluid intake in suitable elective outpatients because contrast agents cause osmotic diuresis. The source material does not specify a fluid regimen, pharmacological prophylaxis, contrast-volume threshold, or laboratory-monitoring schedule.

Haemodynamic complications

Haemodynamic complications are reported in approximately 0.26% of diagnostic angiographic procedures. Hypotension after the procedure may reflect inadequate fluid replacement or occult retroperitoneal haemorrhage after femoral access.

Cardiac perforation, severe arrhythmia, coronary dissection, and no-reflow may each produce rapid haemodynamic deterioration. Patients with cardiogenic shock require transfer as soon as possible to a tertiary centre with invasive capability and an experienced multidisciplinary shock team.

No-reflow phenomenon

No-reflow is characterized by impaired antegrade myocardial perfusion despite the absence of a residual flow-limiting epicardial stenosis. It occurs in up to 2–3% of PCI procedures, particularly during:

• intervention on degenerated saphenous vein grafts;

• rotational atherectomy;

• acute myocardial infarction interventions.

The presumed mechanism is distal embolization of atheromatous or thrombotic debris released during balloon inflation, atherectomy, or stent implantation.

No-reflow is associated with major consequences, including an approximately fivefold higher risk of peri-procedural myocardial infarction and a threefold higher risk of death. Pharmacological approaches, including intracoronary sodium nitroprusside, have been used, but the efficacy of such strategies in reducing subsequent adverse events remains uncertain.

Peri-procedural myocardial infarction

Myocardial infarction during PCI may result from:

• acute thrombotic occlusion;

• severe coronary dissection;

• embolization of thrombus or atherosclerotic material;

• microvascular obstruction;

• side-branch closure at the angioplasty or stent site.

Many peri-procedural infarctions are small and identified only by post-procedure rises in creatine phosphokinase or troponin. The source material associates a less favourable long-term outcome particularly with enzyme elevations exceeding 10 times the upper limit of normal.

Stent thrombosis

All coronary stents are vulnerable to stent thrombosis. Acute thrombosis occurs within 24 hours, and subacute thrombosis between 1 and 30 days. Late thrombosis occurs from 30 days to 1 year, while very late thrombosis occurs after 1 year.

Risk is reduced by:

• complete initial stent deployment;

• appropriate antiplatelet therapy;

• avoidance of premature discontinuation of dual antiplatelet therapy.

Stent thrombosis is associated with death in 10–20% of cases and myocardial infarction in 30–70%. Premature cessation of dual antiplatelet therapy, particularly during the first month after implantation, increases the risk approximately three- to ninefold.

Second-generation drug-eluting stents have lower rates of late and very late thrombosis than first-generation devices. Elective surgery requiring interruption of antiplatelet therapy after drug-eluting stent implantation should, where possible, be postponed beyond 3 months and preferably beyond 6 months.

Restenosis

Restenosis is recurrent narrowing at the site of PCI and is the most frequent PCI complication. Approximate first-year rates are:

Clinical restenosis usually presents with recurrent angina or related symptoms within 12 months. Less commonly, it presents as NSTEMI or STEMI. Confirmation requires demonstrating a significant stenosis at the previous PCI site.

The risk is higher with diabetes, myocardial infarction, long lesions, small-diameter vessels, and a suboptimal initial result. Management of symptomatic restenosis may include repeat PCI with balloon dilation and another drug-eluting stent, drug-coated balloons, brachytherapy, or coronary artery bypass grafting.

Post-procedure management

Monitoring and access-site care

After completion of the procedure, sheaths are removed and haemostasis is achieved according to the access route. Patients should remain in a monitored setting during the immediate recovery period.

Following elective outpatient catheterization, post-procedure instructions include:

• maintaining or increasing fluid intake when clinically appropriate;

• avoiding strenuous activity;

• inspecting the access site for bleeding, swelling, pain, or other signs of complication.

Overnight hospitalization may be needed for patients with important comorbidities, complications during catheterization, or a complicated PCI.

Bed rest and discharge

After femoral access, manual compression or a closure device is used to secure the arteriotomy. Closure devices may reduce the required period of supine rest but are not definitively superior to manual compression for preventing access-site complications.

After radial access, a wristband maintains local pressure while preserving arterial flow, and bed rest is generally approximately 2 hours.

Radiation surveillance

Patients receiving more than 2 Gy during the procedure should be examined for erythema. When exposure exceeds 5 Gy, clinical follow-up within 1 month is recommended to assess for radiation-related skin injury.

Infective complications

Infections are exceptionally uncommon in immunocompetent patients, and routine prophylactic antibiotic therapy is generally not required.

Antiplatelet treatment after PCI

Clopidogrel

Clopidogrel is an irreversible P2Y12 inhibitor and a prodrug requiring hepatic metabolic activation. A standard maintenance dose is 75 mg daily. Maximum inhibition with the standard dose develops over 3–5 days.

A 600 mg loading dose produces more rapid platelet inhibition, generally within 2 hours, than a 300 mg loading dose and is associated with improved clinical outcomes, including lower stent-thrombosis rates. Current guidance recommends a 600 mg loading dose before or during PCI when clopidogrel is used.

For chronic coronary disease patients undergoing drug-eluting stent PCI, clopidogrel remains the preferred P2Y12 inhibitor. Dual antiplatelet therapy with low-dose aspirin should continue for at least 6 months when bleeding risk is not high. A shorter course of 1–3 months may be considered in patients at high bleeding risk.

After bare-metal stent placement, clopidogrel should be continued for at least 1 month and ideally up to 12 months, unless bleeding risk dictates a minimum duration of 2 weeks. Contemporary drug-eluting stents do not appear less safe than bare-metal stents; they have similar or higher risks of stent thrombosis in some comparisons and lower repeat-revascularization rates.

Reduced-function CYP2C19 alleles may produce lower active-metabolite levels, weaker platelet inhibition, and higher cardiovascular event rates with clopidogrel. Routine point-of-care platelet testing or genetic testing has not been shown to be clinically useful for treatment allocation.

Prasugrel

Prasugrel is a potent, irreversible P2Y12 inhibitor with rapid onset. The regimen described in the source material is a 60 mg loading dose followed by 10 mg daily.

It is indicated for patients with acute coronary syndrome undergoing PCI and is not supported for medically managed ACS, in which it may increase bleeding without providing ischaemic benefit. The source material reports greater platelet inhibition and lower ischaemic event rates than clopidogrel in a PCI-treated ACS population, but also more major, life-threatening, and fatal bleeding.

Ticagrelor

Ticagrelor is an orally active, reversible P2Y12 inhibitor. The described regimen is a 180 mg loading dose followed by 90 mg twice daily.

It provides faster and more consistent platelet inhibition than clopidogrel. It is recommended for patients with NSTE-ACS without contraindications who are managed invasively or with an ischaemia-guided strategy, and is preferred over clopidogrel in this setting. In ACS patients undergoing PCI, prasugrel is preferred over clopidogrel when appropriate.

Ticagrelor has not been associated with a significant difference in overall major bleeding compared with clopidogrel in the cited evidence, but non-CABG-related major bleeding is higher.

In patients with ACS who have tolerated dual antiplatelet therapy with ticagrelor, transition to ticagrelor monotherapy at least 1 month after PCI may reduce bleeding risk.

Cangrelor

Cangrelor is an intravenous, reversible P2Y12 inhibitor with a plasma half-life of less than 10 minutes. It acts immediately after bolus administration, and platelet function generally returns within 1–2 hours after stopping the infusion.

It can be used when rapid, potent and reversible platelet inhibition is required during PCI. The source material reports reduced peri-procedural ischaemic events and stent thrombosis compared with clopidogrel, with more combined major and minor bleeding but no increase in transfusion.

Guideline-based access strategy

The principal recommendations supported by the source material are:

• Radial access should be considered first for coronary angiography.

• Radial access is the preferred route for invasive assessment, with or without PCI, in acute coronary syndrome.

• Femoral access remains an appropriate alternative when haemodynamic or technical considerations favour it.

• Low-osmolar or iso-osmolar contrast agents are preferred.

• Contrast-induced acute kidney injury risk should be assessed and mitigated through appropriate pre- and post-procedure care.

• Intravascular imaging can improve outcomes in complex coronary lesions and during revascularization.

• Dual antiplatelet therapy is required after stent implantation, with duration individualized according to the indication, ischaemic risk, bleeding risk, and stent type.

• Patients requiring both anticoagulation and antiplatelet therapy should generally receive an anticoagulant plus a P2Y12 inhibitor rather than prolonged triple therapy.

• Elective surgery requiring interruption of antiplatelet treatment after drug-eluting stent implantation should preferably be delayed beyond 6 months when feasible.

Prognosis and follow-up

Most diagnostic angiographic procedures are completed without major complication, and serious events remain uncommon. Prognosis is worse when complications include contrast-induced acute kidney injury, major bleeding, stroke, peri-procedural myocardial infarction, no-reflow, stent thrombosis, or haemodynamic collapse.

Long-term outcome after PCI depends on the initial procedural result, the occurrence of restenosis or stent thrombosis, the adequacy and duration of antiplatelet therapy, and the balance between recurrent ischaemic risk and bleeding risk.

Follow-up should include:

• assessment of the access site;

• review of symptoms suggesting recurrent angina or restenosis;

• evaluation for delayed bleeding or renal dysfunction when clinically indicated;

• reinforcement of antiplatelet adherence;

• surveillance for radiation-related skin injury after high-dose exposure;

• early review of high-risk patients, including those with substantial comorbidity or intra-procedural complications.

The source material does not specify a universal laboratory or imaging follow-up schedule after uncomplicated angiography. A tailored approach is therefore required, with intensified observation after complex PCI, significant bleeding, renal impairment, high radiation exposure, or any procedural complication.